Macque

该计划项目的长期目标是开发针对粘膜SIV(和HIV)的疫苗策略 未来)传播，特别注重确定导致 保护B细胞的发育和抗体的产生。 灵长类核心的目标是提供实验动物和支持 促进有效完成项目1、2、3和4所述目标所需的服务。 这将包括提供无逆转录病毒的成年雌性耶克斯恒河猴。 猕猴繁殖群体；使用各种免疫平台进行免疫(项目1和2) 样本采集(适用于所有项目)和SIVsmE660重复低剂量阴道挑战。灵长类动物 核心任务还包括对实验动物的日常监测；定期体检 用于免疫学和病毒学评估的血液采集以及样本的采购/运送到 计划项目投资人；根据需要执行CBCs和实验室分析；执行 项目3和项目4的样本采集和处理的安乐死；以及基本的总体业绩 和组织学尸检评估所有实验动物的死亡或在过程中牺牲 这项研究。 提供这些资源和支助服务将有助于开发和检测新型艾滋病 本计划项目中提出的疫苗概念。灵长类核心将在开发中发挥关键作用 一种预防SIV和HIV粘膜传播和致病性的疫苗及其检测 这种保护的关联性。疫苗的效力将根据其1)防止感染的能力进行评估 感染(消毒免疫)或2)显著 挑战后病毒血症的控制和保护性免疫反应的保存。

The long-range goal of this Program Project is to develop vaccine strategies against mucosal SIV (and HIV in the future) transmission, with a special focus on identifying local and systemic mechanisms leading to protecfive B cell development and antibody production. The objectives for the Primate Core are to provide the experimental animals and support services needed to facilitate the efficient completion of the aims outlined in Project 1, 2, 3 and 4. This will include the provision of retrovirus-free adult female rhesus macaques from the Yerkes rhesus macaque breeding colonies; immunizafions using the various immunizafion platforms (Projects 1 and 2) sample collections (for all projects) and repeated low dose vaginal challenges with SIVsmE660. The Primate Core tasks also include daily monitoring ofthe experimental animals; periodic physical examinafions with blood collecfions for immunologic and virologic evaluations and procurement/shipment of samples to the Program Project invesfigators; the performance of CBCs and laboratory analyses as needed; Perform euthanasia with sample collecfion and processing for Projects 3 and 4; and the performance of a basic gross and histologic necropsy evaluations of all experimental animals that die or are sacrificed during the course of this study. Provision of these resources and support services will facilitate the development and testing of novel AIDS vaccine concepts proposed in this Program Project. The Primate Core will play a key role in the development of a vaccine to prevent mucosal transmission and pathogenicity of SIV and HIV and the determination Of correlates of such protection. Vaccine efficacy will be evaluated by its ability to 1) prevent acquisition of infecfion (sterilizing immunity) or 2) significant control of viremia post-challenge and preservation of protective immune responses.